Research and Markets: Asia Pacific Pharma Sector Analysis - The Industry is Projected to Grow at a CAGR of around 12.6% During 2010-2012

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/e201bb/asia_pacific_pharm) has
announced the addition of the "Asia Pacific Pharma Sector Analysis" report to
their offering.

The world continues to witness significant shift in the global pharmaceutical
market landscape, with Asia-Pacific emerging as the fastest growing
pharmaceutical market over the recent past. With low costs and favourable
regulatory environment, the region has seen significant developments in the
field of contract manufacturing, particularly in generics and APIs. Several
technological advancements have also boosted the R&D activities in the region,
helping the market to grow at double digit growth rate in recent years. The size
of the Asia-Pacific pharma market is estimated at around US$ 187 Billion for
2009.

According to our latest research report "Asia Pacific Pharma Sector Analysis",
the future of pharma industry in the Asia-Pacific region remains bright, and the
industry is projected to grow at a CAGR of around 12.6% during 2010-2012. The
growth will mainly be driven by low cost factors, changing regulatory
environment and increased private sector investments in the industry. Currently,
the market is characterized by high growth of generics, and the same trend will
continue in near future also.

We have found that the region will become the global API production hub in next
few years, backed by low cost manufacturing, favorable regulatory environment
and current advancements in the production technology. Also, the market will
show significant changes in terms of sales and marketing model, which will be
changed into tender-based model, favouring the sales of low cost drugs, and thus
resulting in intense competition among key players.

Our research reveals that the pharma sales are growing rapidly in countries like
India, China, Malaysia, South Korea and Indonesia. This growth is mainly
attributed to the increase in disposable income along with the emergence of
several health insurance schemes, which are giving a boost to the sales of
branded drugs. Besides this, the intense competition among key players in the
region has been easing the availability of low cost drugs, thus providing a
further boost to the market growth.

Our report provides an extensive and objective analysis on the Asia-Pacific
pharma market. It provides analytical and statistical information on regional
level markets, including their market size and segmentation. It also features an
analysis on the future directions, supplemented with various facts and figures.
Thus, the report serves as a useful guide for pharmaceutical companies,
government officials, consultants and investors who are planning to enter the
Asia-Pacific pharma market.

Key Topics Covered:

1. Analyst View

2. Global Pharmaceutical Market Overview

3. Asia-Pacific Pharmaceutical Market Overview

4. Pharmaceutical Market By Country

5. Emerging Market Trends

6. Industry Restraints and Recommendation

7. Competitive Landscape

Companies Mentioned:

* GlaxoSmithKline plc
* Pfizer Inc
* Sanofi-Aventis
* Ranbaxy Laboratories Limited
* Takeda Pharmaceutical Company Limited

For more information visit
http://www.researchandmarkets.com/research/e201bb/asia_pacific_pharm

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2009